Interview with Ronald Christie, VP Interntaional Operations – General…
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
Address: East Third Ring Road, Chaoyang District, Beijing No. 1 World Financial Center, East Building 18 Zip Code: 100020
Tel: +86 (010) 59615858
Web: http://www.novonordisk.com.cn/documents/home_page/document/index.asp
Novo Nordisk’s products were introduced to the Chinese market as early as the 1960s. In 1994 Novo Nordisk decided to invest in China by setting up Novo Nordisk (Tianjin) Biotechnology Co., Ltd., which was later renamed Novo Nordisk (China) Pharmaceuticals Co., Ltd.
Headquartered in Beijing, Novo Nordisk now employs more than 1,700 employees and has:
• regional offices in Shanghai, Guangzhou, Wuhan, Shenyang, Jinan and Hong Kong,
• production facilities in Tianjin
• a R&D center in Beijing.
Step by step, Novo Nordisk has become the leader in diabetes in China, with a complete organization covering R&D, production, sales and distribution networks.
While providing all major diabetes treatment products and comprehensive diabetes care to people with diabetes in China, Novo Nordisk is also committed to China’s environment and society and has launched social programs such as for example the NovoCare Bus, the NovoCare Club and the “NovoCare Sunshine Program” in Xinjiang, which is an insulin donation program in an earthquake-ravaged area.
R & D, diabetes treatment products, haemostasis management, hormone replacement therapy
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
Writing in the March 2022 edition of DIA’s Global Forum magazine, Jessie Zhu of Deltamed Co. Ltd./Pharmaron Clinical and Monica Juping Xu of Taimei Medical Technology outline the progress of…
Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and…
A selection of recent top stories from the Chinese pharma industry, including China’s conditional approval of Pfizer’s COVID treatment pill Paxlovid; a new push to combat monopoly practices and unfair…
PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…
Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s…
The latest news from Chinese pharma, including an examination of the new national reimbursement drug list (NRDL), the therapies that have and have not made it onto the list, and…
The phenomenal success of the Pfizer/BioNTech and Moderna COVID-19 vaccines has catapulted messenger RNA (mRNA) vaccines into public consciousness, and mRNA technology is today receiving more scientific and financial attention…
Perhaps Chinese biotech’s biggest success story, cancer-focused Beigene has evolved from the commitment of founders John Oyler and Xiaodong Wang to conducting clinical research in China with a global outlook.…
Portuguese national Isabel Afonso, a Novartis and Sandoz veteran of almost 20 years, has taken on a new role as general manager of Novartis’ highly strategic oncology franchise in China…
The latest news from Chinese pharma, including a new report showing that despite the increasing number of Priority Review and Breakthrough Therapy designations awarded within China, only two Accelerated Approval…
The latest news from Chinese pharma and biotech, including BMS’ attempts to pull out of its Abraxane supply deal with local player BeiGene; a conversation with Qihan Biotech CEO Luhan…
The following is an overview from Accestra Consulting* of Part 2 of China’s Center for Drug Evaluation (CDE)’s 2020 reporting, including an overview of administrative drug approvals and fast track…
See our Cookie Privacy Policy Here